Reporting harms more transparently in trials of cancer drugs

This analysis of 122 Phase II or III trials of cancer drugs published in the five major medical journals in 2016 found 53 (43%) contained terms that downplayed harms; of these 14 had no data on severe adverse events, 22 had no data on serious events, and 2 had no data on deaths.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news